Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study

Basit Öğe Kaydı
dc.contributor.authorArtaç, Mehmet
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorBozkurt, Oktay
dc.contributor.authorBilici, Ahmet
dc.contributor.authorÇelik, S.
dc.contributor.authorÖzçelik, M.
dc.contributor.authorÖven, B.
dc.contributor.authorŞimşek, E.
dc.contributor.authorGeredeli, C.
dc.contributor.authorKaraca, M.
dc.contributor.authorCil, T.
dc.contributor.authorHarputluoğlu, Hakan
dc.contributor.authorŞendur, Mehmet Ali Nahit
dc.contributor.authorTürk, H. Mehmet
dc.contributor.authorKefeli, Umut
dc.contributor.authorAlacacıoğlu, Ahmet
dc.contributor.authorTural, D.
dc.contributor.authorSakin, A.
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorÇevik, Duygu
dc.contributor.authorDane, Faysal
dc.contributor.authorGümüş, Mahmut
dc.date.accessioned2022-08-12T07:33:50Z
dc.date.available2022-08-12T07:33:50Z
dc.date.issued2022
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: Randomized clinical trials showed that maintenance chemotherapy plus biologics in patients with mCRC could increase the progression free survival (PFS) without any advantage for overall survival (OS). Our aim was to study the real-life experience (onco-colon registry Turkey) of maintenance chemotherapy with antiEGFR or antiVEGF mAbs after the standart firstline doublet chemotherapy backbone in RAS wild-type mCRC patients.
dc.description.sponsorshipAmgenen_US
dc.identifier.citationArtaç, M., Çubukçu, E., Bozkurt, O., Bilici, A., Çelik, S., Özçelik, M. ... Gümüş, M. (2022). Real-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study. Annals of Oncology içinde (S281-S282. ss.). https://doi.org/10.1016/j.annonc.2022.04.182
dc.identifier.doi10.1016/j.annonc.2022.04.182
dc.identifier.endpageS282
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.issueSupplement:4
dc.identifier.startpageS281
dc.identifier.urihttps://doi.org/10.1016/j.annonc.2022.04.182
dc.identifier.urihttps://hdl.handle.net/20.500.12511/9646
dc.identifier.volume33
dc.identifier.wos000823826500105en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBilici, Ahmet
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofAnnals of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectMetastatic Colon Cancer (mCRC)
dc.subjectChemotherapy
dc.subjectOnco-Colon Turkey Study
dc.titleReal-life experience with maintenance chemotherapy plus biologics after the first-line treatment of RAS wild-type metastatic colon cancer (mCRC): A multicenter Onco-Colon Turkey study
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bilici-Ahmet-2022.pdf
Boyut:
146.44 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu